415 related articles for article (PubMed ID: 22865271)
1. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.
Thomsen HS; Morcos SK; Almén T; Bellin MF; Bertolotto M; Bongartz G; Clement O; Leander P; Heinz-Peer G; Reimer P; Stacul F; van der Molen A; Webb JA;
Eur Radiol; 2013 Feb; 23(2):307-18. PubMed ID: 22865271
[TBL] [Abstract][Full Text] [Related]
2. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.
Rees O; Agarwal SK
Clin Radiol; 2010 Aug; 65(8):636-41. PubMed ID: 20599066
[TBL] [Abstract][Full Text] [Related]
3. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
Varela CU; Prieto-Rayo JC
Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
[TBL] [Abstract][Full Text] [Related]
4. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
[TBL] [Abstract][Full Text] [Related]
5. Nephrogenic systemic fibrosis: a systemic fibrosing disease resulting from gadolinium exposure.
Bernstein EJ; Schmidt-Lauber C; Kay J
Best Pract Res Clin Rheumatol; 2012 Aug; 26(4):489-503. PubMed ID: 23040363
[TBL] [Abstract][Full Text] [Related]
6. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
7. Current status of nephrogenic systemic fibrosis.
Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
[TBL] [Abstract][Full Text] [Related]
8. Gadolinium and nephrogenic systemic fibrosis: an update.
Weller A; Barber JL; Olsen OE
Pediatr Nephrol; 2014 Oct; 29(10):1927-37. PubMed ID: 24146299
[TBL] [Abstract][Full Text] [Related]
9. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.
Reiter T; Ritter O; Prince MR; Nordbeck P; Wanner C; Nagel E; Bauer WR
J Cardiovasc Magn Reson; 2012 May; 14(1):31. PubMed ID: 22607376
[TBL] [Abstract][Full Text] [Related]
10. Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis.
Padilla-Thornton A; Zand KR; Barrett B; Stein L; Andrew G; Forster BB
Can Assoc Radiol J; 2008 Dec; 59(5):237-40. PubMed ID: 19385151
[No Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
Jalandhara N; Arora R; Batuman V
Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
[No Abstract] [Full Text] [Related]
12. The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents.
Costa AF
Can Assoc Radiol J; 2020 Nov; 71(4):536. PubMed ID: 32063014
[No Abstract] [Full Text] [Related]
13. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
Thomsen HS
Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
[No Abstract] [Full Text] [Related]
14. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.
Smorodinsky E; Ansdell DS; Foster ZW; Mazhar SM; Cruite I; Wolfson T; Sugay SB; Iussich G; Shiehmorteza M; Kono Y; Kuo A; Sirlin CB
J Magn Reson Imaging; 2015 May; 41(5):1259-67. PubMed ID: 24811860
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
16. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
18. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium and nephrogenic systemic fibrosis: have the alarm bells been silenced?
Tamburrini O; Balducci A
Radiol Med; 2012 Feb; 117(1):1-5. PubMed ID: 22020430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
